|
Dr. Nelson is Vice President of Global Corporate Development and Strategy, Invitrogen Corporation and provides Fluorophamra with over 15 years of combined scientific and investment expertise. Dr. Nelson was most recently the Senior Managing Partner and Founder of Lokoya Capital, a life sciences merchant banking and venture capital firm. Dr. Nelson has also held positions as Managing Director and Head, Global Biotechnology Research and Corporate Strategy at RBC Capital Markets (formerly Dain Rauscher Wessels), a division of the Royal Bank of Canada, a $30 billion commercial and investment bank. While at RBC Capital Markets and its predecessor company, Dr. Nelson was responsible for increasing the firm’s cumulative participation in the life sciences equity capital markets to more than $6 billion. Prior to that, Dr. Nelson was also a First Vice President, Global Healthcare Securities Research and Economics for Merrill Lynch & Co. in New York and Vice President in biotechnology equity research at Josephthal & Company in New York. Instrumental in building several of the industry’s leading institutional and private equity life sciences franchises, Dr. Nelson has been a managing underwriter of more than 30 life sciences transactions. His work has been widely published in both the scientific and investment communities. Dr. Nelson served previously as a member of the advisory board to the Royal Bank of Canada’s Life Science Fund and currently serves as a member of the Board of Directors for NexGen Medical Systems, Inc., and Progentec LLC. Dr. Nelson received his MBA magna cum laude from the Carlson School of Management at the University of Minnesota with an emphasis on financial valuation models for the biotechnology industry. | 